BioHarvest Sciences, Inc. · NASDAQ:BHST
BioHarvest Sciences — Investor Presentation (June 2024)
21 slides from BioHarvest Sciences's investor presentation, June 2024
Slide 1: The Botanical Synthesis Company Investor Presentation
The Botanical Synthesis Company Investor Presentation June 2024 CSE: BHSC | OTCQB: CNVCF
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements." The statements contained in this presentation that are not purely historical are forward-looking statements. Forward-looking statements give the Company's current expectations or forecasts of future events. Such stat
Slide 3: Corporate Overview
Corporate Overview BioHarvest Sciences is a biotech innovator & inventor of Botanical Synthesis – a new process to synthesize plant-based molecules – providing the world with consistent, reliable, economically viable & patentable potent molecules for the next generation of therapeutic solutions. • P
Slide 4: Market Opportunity
Market Opportunity Addressing Unmet Medical Needs with Patentable Plant Molecules Product Business Unit – D2C Model Industry Demand for Health & Wellness • The U.S. consumer wellness market is $480 billion, Natural expected to grow at a 5 –10% annual rate1 o 82% of U.S. consumers consider wellness a
Slide 5: Invested $100M into Proprietary Technology Process
Invested $100M into Proprietary Technology Process Which Enables Development of Molecules for Next-Gen Therapeutic Solutions Botanical Synthesis allows for the perpetual creation of consistent botanical molecules, requiring the plant only one time, giving BioHarvest the ability to Address Unmet Medi
Slide 6: Turning Plants Into a Scientifically Reliable Source of Patentable Biological Molecules
Turning Plants Into a Scientifically Reliable Source of Patentable Biological Molecules BioHarvest’s Botanical Synthesis Process Provides New Botanical Synthesis Offers Significant Advantages Solutions for Pharma to Address Unmet Medical Needs Plants possess an infinite source of molecules with hist
Slide 7: Product Business Unit
Product Business Unit Applying Botanical Synthesis to Consumer-Grade Applications BioHarvest Sciences Product Service CDMO Business Unit Business Unit CSE: BHSC | OTCQB: CNVCF 7
Slide 8: Introducing VINIA: Our Flagship Red Grape Cell-Derived Nutraceutical Product
Introducing VINIA®: Our Flagship Red Grape Cell-Derived Direct-to-Consumer Nutraceutical Product • VINIA® is BioHarvest’s first commercial product, a proprietary nutraceutical containing the entire matrix of red grape polyphenols, including Piceid Resveratrol • Botanical Synthesis process increases
Slide 9: Products Anchored in Science & Backed by Clinical Trials
Products Anchored in Science & Backed by Clinical Trials Clinical trial published in peer reviewed scientific journals bioharvest.com/clinical-studies *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any d
Slide 10: Scaling Grape Molecule Across New Higher Margin Verticals in Next 24 Months
Scaling Grape Molecule Across 3 New Higher Margin Verticals in Next 24 Months Testament to BioHarvest’s Ability to Scale and Enter New Markets VINIA Capsules VINIA Hot Beverages VINIA Hydration VINIA Skincare Products Flagship Nutraceutical Launched December 2023 Launching H1 2025 Launching H1 2025
Slide 11: Repeating the VINIA Playbook: Olive & Pomegranate Cells
Repeating the VINIA Playbook: Olive & Pomegranate Cells Business Model Can be Easily Replicated Across New Plant Molecules Olive Cell & Pomegranate Cell Molecules to be Launched in H1 2025 & H1 2026 Respectively • Olives: Providing at least 15X concentrated amounts of Verbascoside concentration vs.
Slide 12: Introducing Service Business Unit
Introducing Service Business Unit Applying Botanical Synthesis as a CDMO: Contract Development & Manufacturing Organization BioHarvest Sciences Product Service CDMO Business Unit Business Unit CSE: BHSC | OTCQB: CNVCF 12
Slide 13: Introducing CDMO Products & Services
Introducing CDMO Products & Services BioHarvest Sciences Botanical Synthesis CDMO has the Potential to Become an Emerging Force in Plant-based Biologics Development • Newly launched expansion into the contract development & manufacturing organization (CDMO) market, built upon the success of its comm
Slide 14: Demand Centers & Addressable Market
Demand Centers & Addressable Market CDMO Building Blocks for Growth Pharma & Biotech Nutraceuticals Pharma: (a) Over 140 existing Rx small molecules utilize plant-based Major Health and API, KSM, or excipients (b) pursuit of Wellness focus driven by new molecules in clinical Ph1+ preventative medici
Slide 15: CDMO Staged Development Process
CDMO Staged Development Process Two Contracts Already Signed with Tier-1 Partners Across Multiple Verticals • Contracts signed with leading Nasdaq-listed pharmaceutical company and a major food ingredients industry player • Platform is resonating with industry: In advanced negotiations with several
Slide 16: The CDMO Sales Funnel: An Illustrative Case Study
The CDMO Sales Funnel: An Illustrative Case Study Each Ten Projects Could Generate $100M+ in Revenue Over 5-Years CDMO Projects Continuous Contract Manufacturing ~15-24 Month Development Cycle Predictable, High-Margin Royalty Revenues ~$1.8-2.5M in NRE Revenue per Project Targeting Two New Projects
Slide 17: In-House Biotech Manufacturing and R&D Facilities
In-House Biotech Manufacturing and R&D Facilities World Class Biological Production and R&D Team in Israel • BioHarvest is currently producing VINIA in a state-of-the-art biological production facility in the center of Israel • Production facility located in Yavneh, Israel • Corporate and R&D office
Slide 18: Financial Highlights
Financial Highlights Quarterly • Success of VINIA® Red Grape Cell product line drove FY23 revenues to a record of $12.7 Revenue* million, reflecting an increase of 131% over 2022 $ in Millions • 90% of VINIA.com revenue is generated from recurring subscriptions $5.7 • 91% of those on subscriptions o
Slide 19: Management Team with Track Record of Innovation & Commercial Excellence
Management Team with Track Record of Innovation & Commercial Excellence Ilan Sobel Chief Executive Officer Dr. Zaki Rakib 25+ years developing & executing strategic growth strategies Chairman of the Board 30+ years experience developing disruptive technologies Dr. Yochi Hagay Chief Technology Office
Slide 20: Investment Highlights
Investment Highlights • BioHarvest Botanical Synthesis process technology represents a generational opportunity for pharmaceutical and health & wellness markets o Patented technology platform optimizes the production of the phyto-medicinal molecules in plants to develop pharmaceutical and health and
Slide 21: Contact Us
Contact Us Investor Lucas A. Zimmerman Main: (949) 259-4987 Relations MZ North America [email protected] BioHarvest Sciences (CSE: BHSC | OTCQB: CNVCF) 625 Howe Street Suite 1140 Vancouver, BC V6C 2T6 Canada www.bioharvest.com 21
BioHarvest Sciences — Investor Presentation (June 2024) on 6ix